Cargando…

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

BACKGROUND: Tuberculosis remains a huge public health problem and the prolonged treatment duration obstructs effective tuberculosis control. Higher rifampicin doses have been associated with better bactericidal activity, but optimal dosing is uncertain. This analysis aimed to characterize the relati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Svensson, Elin M, Svensson, Robin J, te Brake, Lindsey H M, Boeree, Martin J, Heinrich, Norbert, Konsten, Sarah, Churchyard, Gavin, Dawson, Rodney, Diacon, Andreas H, Kibiki, Gibson S, Minja, Lilian T, Ntingiya, Nyanda E, Sanne, Ian, Gillespie, Stephen H, Hoelscher, Michael, Phillips, Patrick P J, Simonsson, Ulrika S H, Aarnoutse, Rob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005123/ https://www.ncbi.nlm.nih.gov/pubmed/29917079 http://dx.doi.org/10.1093/cid/ciy026

Ejemplares similares

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)

Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
por: Susanto, Budi O, et al.
Publicado: (2019)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
por: Ayoun Alsoud, Rami, et al.
Publicado: (2023)

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: te Brake, Lindsey H. M., et al.
Publicado: (2019)

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
por: Boeree, Martin J, et al.
Publicado: (2017)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
por: Stemkens, Ralf, et al.
Publicado: (2023)

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)
por: Phillips, Patrick P. J., et al.
Publicado: (2016)

Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
por: Faraj, Alan, et al.
Publicado: (2020)

Forecasting Clinical Dose–Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With Rifampicin
por: Wicha, Sebastian G., et al.
Publicado: (2018)

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance
por: Martinecz, Antal, et al.
Publicado: (2023)

Improved power for TB Phase IIa trials using a model-based pharmacokinetic–pharmacodynamic approach compared with commonly used analysis methods
por: Svensson, Robin J., et al.
Publicado: (2017)

Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials
por: Svensson, Elin M, et al.
Publicado: (2019)

Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin‐Treated Pulmonary Tuberculosis
por: Svensson, RJ, et al.
Publicado: (2016)

Tuberculosis Molecular Bacterial Load Assay Reveals Early Delayed Bacterial Killing in Patients With Relapse
por: Ntinginya, Nyanda Elias, et al.
Publicado: (2022)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
por: Keutzer, Lina, et al.
Publicado: (2022)

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre
por: Seijger, Charlotte, et al.
Publicado: (2019)

Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
por: Keutzer, Lina, et al.
Publicado: (2020)

Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?
por: Dutta, Noton K., et al.
Publicado: (2015)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
por: Abulfathi, Ahmed A., et al.
Publicado: (2021)

Residual Spinal Cord Compression Following Hemilaminectomy and Mini-Hemilaminectomy in Dogs: A Prospective Randomized Study
por: Svensson, Gustaf, et al.
Publicado: (2017)

New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
por: Aguilar Diaz, Jessica M, et al.
Publicado: (2023)

Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy
por: Ahmed, Mohamed I. M., et al.
Publicado: (2018)

A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells—using rifampicin as an example
por: Clewe, Oskar, et al.
Publicado: (2015)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial
por: Cresswell, Fiona V, et al.
Publicado: (2021)

Improving treatment outcome assessment in a mouse tuberculosis model
por: Mourik, Bas C., et al.
Publicado: (2018)

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
por: Stott, K E, et al.
Publicado: (2018)

Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease
por: Danho, Rabi, et al.
Publicado: (2022)

The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease
por: Schildkraut, Jodie A., et al.
Publicado: (2023)

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
por: Svensson, Elin M., et al.
Publicado: (2015)

Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
por: Mudde, Saskia E, et al.
Publicado: (2021)

High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo
por: Hu, Yanmin, et al.
Publicado: (2015)

Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
por: Faraj, Alan, et al.
Publicado: (2020)

Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients
por: te Brake, Lindsey H.M., et al.
Publicado: (2018)

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
por: Dierig, A, et al.
Publicado: (2023)

Seasonal influence on respiratory tract infection severity including COVID‐19 quantified through Markov Chain modeling
por: van Wijk, Rob C., et al.
Publicado: (2023)

Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Dooley, Kelly E., et al.
Publicado: (2020)

Early mortality during rifampicin-resistant TB treatment
por: Mohr-Holland, E., et al.
Publicado: (2022)

Rifampicin Resistance in Tuberculosis Outbreak, London, England
por: Jenkins, Claire, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_4aaul9eeu7bfk6ekrrksjdvmrn